- Cytolon and T-Cell Europe agree on cooperation
- Cytolon initiates global development of DIT - Distributed-Inventory-TechnologyTM
- Cytolon joins Personalized Medicine Coalition
- Cytolon successful with second financing round
- Cytolon gains Patent for CordMatch® in Australia
- Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
- Timm Jessen Joins Cytolon’s Supervisory Board
- Cytolon Partners with iSoft for New Life Science Research Tool
- Michaela Servas joins Cytolon´s Supervisory Board
- Cytolon Co-Founder Prof. Dr. Joachim Dudenhausen receives Order of Merit
- CordMatch® goes live
- Cytolon Partners with CSC to Develop CordMatch®
- Cytolon Closes Its First Round of Financing
- Wolfgang Jünger Joins Cytolon's Supervisory Board
- Katherina Reiche, MdB, Steps Down From Cytolon's Supervisory Board to Become a Member of the Federal Government of Germany
- Cytolon Receives the "MOST PROMISING COMPANY LAUNCHED IN 2009 AWARD"
- Cytolon Announces Cooperative Agreement with ARCWAY
- Start-up Financing Begins
- The Launching of Cytolon AG
Cytolon and DKMS Cord Blood Bank announce collaboration for CordMatch’s Beta-Testing Phase
Cytolon has gained DKMS Cord Blood Bank as a partner for the important beta-testing phase of CordMatch®. The DKMS Cord Blood Bank is a 100% owned subsidiary of the DKMS German Bone Marrow Donor Registry GmbH, the largest stem cell donor center worldwide with over 30% of the market share of donated stem cell units.
Berlin/Dresden 08 March 2011. CordMatch® is a unique and newly developed IT platform that connects cord blood banks and registries with transplant centers and offers an optimal solution to identify matching cord blood units for leukemia patients. The web-based platform is the first to provide complete process chain management from match identification through follow-up within one integrated system.
“We are very pleased that we have gained DKMS Cord Blood Bank as a partner for the important beta-testing phase of CordMatch®. The DKMS Cord Blood Bank is a 100% owned subsidiary of the DKMS German Bone Marrow Donor Registry GmbH, the largest stem cell donor center worldwide with over 30% of the market share of donated stem cell units,” said Thomas Klein, the CEO of Cytolon AG. Klein continued, “The cord blood bank in Dresden will fulfill all international accreditation standards and is a world leader in providing comprehensive and high resolution genetic data sets for every stem cell unit. The DKMS Cord Blood Bank is therefore an ideal partner for the conclusion of testing prior to the market launch of CordMatch®”.
Dr. Alexander Schmidt, CEO of DKMS Cord Blood Bank is confident that CordMatch® is an important tool to offer cord blood units to a wider spectrum. “We believe that CordMatch® is an important innovation for the whole field of care of leukemia patients, and are therefore keen to secure collaboration early.” Dr. Alexander Platz, the medical director of the cord blood bank in Dresden sees important synergies with the strategy of the DKMS Cord Blood Bank. “With our cord blood bank we are preparing for strong growth in the area of cord blood units. In addition to increasing investments in our headquarters in Dresden, CordMatch® is an ideal service to enable us to offer our cord blood units worldwide.” All involved parties have agreed to work closely together to exchange information and experience during the multi-month beta phase. The market launch of CordMatch® is planned for summer 2011.
About Cytolon
Cytolon AG is a technology oriented service provider positioning itself as the first company worldwide to offer intelligent internet platforms that will become necessary for the field of personalized medicine. Cytolon’s first product is an internet based matching platform, CordMatch®. CordMatch® offers efficient cost saving solutions to transplant centers, donor registries, stem cell banks, and pharmaceutical companies which make it possible to provide individually matched stem cell preparations for a high number of cases worldwide.
Cytolon was founded in 2005 by Thomas Klein. In 2009 Cytolon AG was awarded the “most promising company launched-Award by Deutsche Bank, Hasso Plattner Ventures. Cytolon is a member of the Association of Research-Based Pharmaceutical Companies (VfA) and the Federal Association for Information Technology, Telecommunications and New Media (BITKOM). Further information can be found at www.cytolon.com.
About the DKMS and DKMS Cord Blood Bank
The DKMS Cord Blood Bank is a 100% subsidiary of DKMS German Bone Marrow Donation Registry. The DKMS was founded in 1991 and, with over 2.3m registered donors, is the largest stem cell donor center worldwide. Over 24k donors have already donated stem cells or bone marrow, and thus given a leukemia patient a new chance at life.
The DKMS has been collecting cord blood since 1997 through collaboration with University Clinic Dresden and within the scope of a third party funded project. Since the end of 2008, the non-profit organization, DKMS Cord Blood Bank has been a member of the DKMS family. Cord blood collected for the DKMS Cord Blood Bank is prepared and stored in Dresden. To date this includes over 3,600 preparations. Nationwide there are already 150 cooperating clinics with specially trained personnel collecting donations for the DKMS Cord Blood Bank. Further information can be found at www.dkms-nabelschnurblutbank.de.
Press contact
Hanna Dudenhausen
Public Relations/ Investor Relations
Cytolon AG
mobile +49 (0) 151 291 091 26
phone: +49 (0) 30 26 39 288 0
fax: +49 (0) 30 26 39 288 20
e-mail: hanna.dudenhausen@cytolon.com